Embed Size (px)
Citation preview
Biotechnology for HealthFuture perspectives
Octavi Quintana Trias
Director, Health ResearchDG Research
EC-US Task Force for Biotechnology, 19 July 2006
EC Research Framework Programme 6
(2002-2006)
• Health research priority ~€2.5 billion for research – over 540 projects:
114 Integrated Projects (IPs), 40 Networks of Excellence (NoEs) ~300 Specific Targeted Research Projects (STREPs)and a number of support actions.
• topics for research are set by the EC
• projects are evaluated by external evaluators
• average success rate: 24%
• Consortia receive EC funding for R&D tasks and for project management
Number of participants by partner country in funded proposalsPriority 1 and SARS calls
05
101520253035
United
States
China
Russia
Austra
liaArge
ntina
South
Africa
Canad
aBraz
ilInd
iaYug
oslav
iaGab
onKen
yaUkra
ineCam
eroon
Chile
Hong-K
ong
Japa
nMali
Taiwan
Thaila
ndInternational Participation
in FP6 Health Research
Altogether 207 international participants from 42 countries in 548 projects
Pre-clinical
Discovery
Genomics
• Vaccines (NoE)
• Microbicides (IP)
• Therapy Trials in Europe
•Drugs (IP)
• Vaccines (IP/NoE)•Biology and
Pathology (NoE)
EUROPEAN DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP (EDCTP)
Clinical Trials(Phase II/III)
HIGH RISK PROJECTS (STREPS)DEFINED SUPPORTING ACTIVITIES (SSA)
•Vaccines (IP)
•Drugs (IP)
HIV/AIDS Malaria TB
CROSS-CUTTING TOPICS: Mucosal vaccines for PRD (IP)
Neonatal vaccination strategies for PRD
Early human testingSOME STRUCTURING CAs, SSAs ?
NEW INSTRUMENTS
EDCTP
Health Research in the 7th Framework Programme
2007-2013
Main policy drivers:
Improving the health of European citizens
Increasing the competitiveness of European health-related industries and businesses
Addressing global health issues, including emerging epidemics
Collaborative researchin Health
Activities in 3 main areas
• Biotechnology, generic tools and technologies for human health
• Translating research for human health
• Optimising the delivery of healthcare
Collaborative researchin Framework programme 7
HealthFP7
Activities in 3 main areas
• Biotechnology, generic tools and technologies for human health
• Translating research for human health
• Optimising the delivery of healthcare to European citizens
Collaborative researchin Health
FP7
Budget:
€5984 million over 7 years (2007-2013)
1: Biotechnology, generic tools and technologies
High-throughput research (enhancing data generation, standardisation, acquisition & analysis).
Detection, diagnosis and monitoring (with emphasis on non-invasive or minimally invasive approaches).
Innovative therapeutic approaches and interventions(with potential application in many diseases and disorders).
Predicting suitability, safety and efficacy of therapies (biological markers, in vivo and in vitro methods and models, including simulation, pharmacogenomics, targeting approaches and alternatives to animal testing)
Collaborative researchin Health
FP7
2: Translating research for human health
Integrating biological data and processes: (large-scale data gathering, systems biology)
Research on the brain and related diseases, human development and ageing
Translational research in infectious diseases: to confront major threats to public health (antimicrobial drug resistance, HIV/AIDS, malaria, TB, emerging epidemics)
Translational research in other major diseases: (cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases)
Collaborative research in Health
FP7
3: Optimising the delivery of health care to European citizens
Enhanced health promotion and disease prevention (providing evidence of best public health measures – life styles, interventions, special focus on mental health, etc.)
Translating clinical research into clinical practice (patient safety, better use of medicines, benchmarking, pharmacovigilance, etc.)
Quality, solidarity and sustainability of health systems (organisational and financial aspects, health systems, etc.)
Collaborative research in Health
FP7
Two other issues will be addressed across activities:
Child healthThe health of the ageing population
Collaborative research in Health
FP7
Continuity in collaborative research to develop new tools and technologiespromote translational researchenhanced efforts to optimise delivery of health care
[ using usual FP funding and coordination mechanisms ]&
A novel approach to improve drug developmentThe Innovative Medicines Initiative
[ using the proposed Joint Technology Initiative in FP7 ]
FP7 & Health research
SUMMARYFP7
1.1. All activities open for International CooperationAll activities open for International Cooperation• Third country participation is particularly encouraged in
topics with enhanced international participation• Minimum number of participants: 3 from Europe• Industrialised countries may be funded only if seen
indispensable
2.2. Specific International Cooperation ActionsSpecific International Cooperation Actions• Address research areas identified through bi-regional
dialogues and international for a, on the basis of mutual interest and mutual benefit
International Cooperation in Framework Programme 7
2 different mechanisms:
•• Pandemic InfluenzaPandemic Influenza
•• Global Vaccine Enterprise Global Vaccine Enterprise
•• WorldWorld--Wide Collaborative Effort on Mouse Wide Collaborative Effort on Mouse Functional Genomics Functional Genomics
•• NeuroInformaticsNeuroInformatics ResearchResearch
•• InnovativeInnovative MedicinesMedicines Initiative (IMI)Initiative (IMI)
Topics for EU-US collaboration
More Information
EC funded health research: Framework Programme 6 http://cordis.europa.eu/lifescihealth
Towards Framework Programme 7http://cordis.europa.eu/fp7
Innovative Medicines Initiativehttp://ec.europa.eu/research/fp6/index_en.cfm?p=1_innomed
Contacts:Contacts at the Health Directorate:
Bernard Mulligan ([email protected])Head of unit, Fundamental Genomics unit (F4)
Stéphane Hogan ([email protected])Head of unit, Biotechnology & Applied Genomics unit
Irene Norstedt ([email protected])Head of sector, Innovative Medicines
Alain Vanvossel ([email protected]) Head of unit, Major Diseases
Maria Vidal ([email protected])Head of sector, Cancer
Arnd Hoeveler ([email protected])Head of unit, Communicable diseases related to poverty
Anna Lönnroth ([email protected])Head of sector, Emerging infectious diseases
Kevin McCarthy ([email protected])Head of sector, Public Health
Iiro Eerola ([email protected]) Contact point for International Cooperation
